Effect of Mosapride Citrate on Gastric Emptying in Interferon-Induced Gastroparesis

Abstract

Mosapride improved total and distal gastric motility in IFN-induced gastroparesis, and consequently relieved symptoms.

Gastroparesis

“…A recent report of hepatitis C patients with interferoninduced gastroparesis observed emptying acceleration and symptom reductions with the 5-HT 4 agonist mosapride [35]. Other agents with stomach stimulating effects but unproved benefits in gastroparesis include new 5-HT 4 agonists (prucalopride, velusetrag, naronapride) and acetylcholinesterase inhibitors (acotiamide).…”

Clinical assessment of delayed gastric emptying and diabetic complications using gastric emptying scintigraphy: Involvement of vascular disorder

“…Gastrointestinal symptoms (anorexia, nausea, vomiting, abdominal distension, early satiety, heartburn, belching and epigastric pain) were evaluated at the time of the gastric emptying tests using a questionnaire (Kawamura et al, 2012). Figure 1 Anterior view of the epigastric region in the standing position at 0, 5, 10, 20, 30, 60, 90 and 120 min after intake of a solid meal.…”

YH12852, a potent and highly selective 5‐HT4 receptor agonist, significantly improves both upper and lower gastrointestinal motility in a guinea pig model of postoperative ileus

“…In fact, several 5-HT 4 receptor agonists have already proven their clinical effectiveness in patients with functional GI motility disorders including functional constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. [18][19][20][21] However, some of these agonists such as mosapride (Gasmotin ® ) are only used for upper GI motility disturbances, others including tegaserod (Zelnorm ® ) and cisapride (Propulsid ® ) have been withdrawn from the market due to cardiovascular safety issues thought to arise from poor receptor selectivity. [22][23][24] YH12852 is a novel 5-HT 4 receptor agonist with high in vitro potency (EC 50 =4.8 pm) and selectivity (>200-19,000-fold) for human recombinant 5-HT 4(a) receptors over other 5-HT and non-5-HT receptors, ion channels, enzymes and transporters.…”

“…The 5‐HT 4 receptor is therefore an important drug target for therapeutic strategies intending to stimulate GI motility. In fact, several 5‐HT 4 receptor agonists have already proven their clinical effectiveness in patients with functional GI motility disorders including functional constipation, constipation‐predominant irritable bowel syndrome, functional dyspepsia and gastroparesis . However, some of these agonists such as mosapride (Gasmotin ® ) are only used for upper GI motility disturbances, others including tegaserod (Zelnorm ® ) and cisapride (Propulsid ® ) have been withdrawn from the market due to cardiovascular safety issues thought to arise from poor receptor selectivity .…”